Compare MEI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | STTK |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.5M | 538.3M |
| IPO Year | 1994 | 2020 |
| Metric | MEI | STTK |
|---|---|---|
| Price | $15.78 | $6.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.00 | ★ $10.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 03-05-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | 42.94 | ★ 53.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,300,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $4.88 | $0.71 |
| 52 Week High | $20.38 | $8.33 |
| Indicator | MEI | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 54.97 |
| Support Level | $6.31 | $5.81 |
| Resistance Level | $20.38 | $6.81 |
| Average True Range (ATR) | 1.78 | 0.65 |
| MACD | -0.28 | 0.07 |
| Stochastic Oscillator | 39.65 | 58.50 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.